Research area
Longevity and mitochondrial
Compounds studied for effects on aging, mitochondrial function, or age-related cellular decline. This is one of the least clinically established categories on the site -- most entries here are preclinical or purely investigational.
13 entries in this category.
-
BAM15
Also relevant to longevity and mitochondrial research. BAM15 is a non-peptide mitochondrial uncoupler that reversed diet-induced obesity and insulin resistance in mice without observed toxicity, but it has never been tested in humans. It shares its basic mechanism with DNP, a chemical with a documented history of fatal overheating deaths, and no human dose has ever been established.
* Also filed under: Metabolic and incretin
-
Epithalon
Epithalon (Epitalon) is a synthetic four-amino-acid peptide, AEDG, developed to mimic an older bovine pineal extract called Epithalamin, and best known for a claimed telomerase-activating, anti-aging effect. That claim rests almost entirely on cell-culture work from one Russian research group, with a single independent 2025 in vitro replication; every human study reporting a clinical benefit comes from that same research network or its direct collaborators, uses the older Epithalamin extract rather than the synthetic peptide sold today, was small and mostly open-label, and has never been independently reproduced or registered on ClinicalTrials.gov. This is an educational compilation, not medical advice.
-
FOXO4-DRI
FOXO4-DRI is a synthetic senolytic peptide that selectively triggered apoptosis in senescent cells and improved markers of aging in mice in a widely cited 2017 study. It has not been tested in humans and no human dosage has been established.
-
Humanin
Humanin is a mitochondrial-derived peptide studied in cell and animal research for its ability to protect cells from stress-induced death, with proposed roles in neuroprotection, metabolism, and aging. It has not been tested in human clinical trials and no human dosage has been established.
-
Klotho
Klotho is a naturally occurring anti-aging protein studied in mice and, in one 2023 primate study, aged monkeys for effects on memory and kidney health. It is not a short synthetic peptide, has never been tested in humans, and no human dosage has been established, despite heavy social media discussion.
-
Methylene Blue
Methylene blue is a century-old synthetic drug, FDA-approved to treat methemoglobinemia, that has also become popular off-label in longevity and biohacking communities as a low-dose "nootropic" and mitochondrial-support compound. The approved use has strong clinical evidence; the longevity use does not.
-
MOTS-c
MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA, first described in 2015 for striking metabolic effects in mice, including reversal of diet-induced obesity and restored insulin sensitivity, that have not been tested in a completed human trial; the one registered human study, a Phase 2a trial in prediabetes and obesity, was still recruiting and had reported no results at the time of this compilation, leaving circulating-level associations with obesity, diabetes and PCOS as the only other human data, and no established human dose for any purpose.
-
NAD+
NAD+ is a coenzyme, not a peptide, sold as IV drips, injection kits and nasal sprays at the same clinics that sell peptides. A 2026 systematic review found no eligible outcomes trial of direct NAD+ for anti-aging or wellness use; the one randomized, placebo-controlled human trial found is in ischemic cardiomyopathy heart failure, not wellness or addiction; the addiction-treatment claim rests on one uncontrolled 50-person pilot; a controlled comparison found IV NAD+ causes significantly more GI and cardiac-adjacent symptoms than IV nicotinamide riboside and takes roughly 2.6 times as long to infuse; and an FDA warning letter and Class I recall tie an NAD+ lot to endotoxin contamination and patient harm.
-
NAD+ / MOTS-c / 5-Amino-1MQ
NAD+ / MOTS-c / 5-Amino-1MQ groups a compounded coenzyme, a peptide with one recruiting human trial, and a small molecule with no human data of any kind. No two of the three have been tested together, and 5-Amino-1MQ's oral form means the three cannot share a single injectable vial the way the name implies.
-
NMN
NMN is a naturally occurring precursor the body converts directly into NAD+, a coenzyme central to cellular energy metabolism that declines with age. It has more published human clinical trial data than most longevity supplements, but no single confirmed effective dose and no proof it extends human lifespan.
-
SLU-PP-332
Also relevant to longevity and mitochondrial research. SLU-PP-332 is a non-peptide, pan-ERR receptor agonist studied only in mice as an exercise mimetic. It has never been tested in humans, has no established human dose, and is not approved for any use.
* Also filed under: Metabolic and incretin
-
SS-31
SS-31, also known as elamipretide, is now FDA-approved as FORZINITY for one narrow indication, muscle strength in Barth syndrome, under accelerated approval resting on a surrogate endpoint. Every other use it was tested for, including mitochondrial myopathy, heart failure, heart attack recovery and dry macular degeneration, failed its primary endpoint, and a 2026 FDA warning letter named the same molecule as an unapproved product when sold by research-peptide vendors.
-
Urolithin A
Urolithin A is a gut-bacteria-derived metabolite of pomegranate and walnut compounds, studied for its ability to promote mitophagy (cellular cleanup of damaged mitochondria). A registered, published human trial showed muscle-strength benefits at 500-1,000 mg/day, giving it a stronger human evidence base than most longevity supplements, though broader anti-aging claims remain unproven.